SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.32 CNY | +2.81% |
|
+0.81% | -10.83% |
| Jul. 01 | Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board and Board Committee Changes | CI |
| Jun. 28 | Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug | MT |
| Sales 2024 * | 44.79B 6.16B | Sales 2025 * | 50.5B 6.95B | Capitalization | 54.31B 7.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.36B 462M | Net income 2025 * | 4.12B 568M | EV / Sales 2024 * | 1.56 x |
| Net Debt 2024 * | 15.6B 2.15B | Net Debt 2025 * | 17.72B 2.44B | EV / Sales 2025 * | 1.43 x |
| P/E ratio 2024 * |
17.5
x | P/E ratio 2025 * |
14.3
x | Employees | 40,370 |
| Yield 2024 * |
1.8% | Yield 2025 * |
2.16% | Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.81% | ||
| 1 week | +0.81% | ||
| Current month | +0.81% | ||
| 1 month | -5.50% | ||
| 3 months | -4.37% | ||
| 6 months | -9.08% | ||
| Current year | -10.83% |
1 week
21.65
22.40
1 month
21.6523.92
Current year
20.3825.89
1 year
20.3832.08
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Shirley Wu
DFI | Director of Finance/CFO | 44 | 16-12-31 |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gu Liang Tang
BRD | Director/Board Member | 62 | 19-06-24 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 1 M€ | -23.55% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 22.32 | +2.81% | 11,025,280 |
| 24-07-04 | 21.71 | -1.50% | 8,214,800 |
| 24-07-03 | 22.04 | +0.32% | 5,794,379 |
| 24-07-02 | 21.97 | -0.72% | 4,784,257 |
| 24-07-01 | 22.13 | -0.05% | 7,366,443 |
End-of-day quote Shanghai S.E., July 04, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
22.32
CNY
Average target price
28.61
CNY
Spread / Average Target
+28.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.83% | 7.47B | |
| +56.89% | 823B | |
| +39.52% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.74% | 239B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B |
- Stock Market
- Equities
- 600196 Stock
